Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.